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Abstract
Objectives: 1,25-Dihydroxycholecalciferol (calcitriol, vitamin D3) has immunosuppressive properties. This study evaluates the effect of
calcitriol in combination with either cyclosporine A or tacrolimus on acute lung allograft rejection in a rat model of unilateral left lung
allotransplantation. Methods: Unilateral left lung transplantation was performed in male rats (Brown–Norway to Fischer F344, 200–250 g
body weight). For immunosuppression, the following subtherapeutic doses were used: calcitriol 0.5 mg/kg/day, cyclosporine A
2.5 mg/kg/day i.p., and tacrolimus 40 mg/kg i.m. Five groups ðn ¼ 5Þ were analyzed: cyclosporine A; cyclosporine A and calcitriol;
calcitriol; tacrolimus and calcitriol; and tacrolimus. The injections were performed for 5 days starting from the day of transplantation.
Recipients were sacrificed on day 5 post-transplant. The contralateral right main bronchus and pulmonary artery were occluded for 5 min and
blood was drawn for blood gas analysis. The grafts were excised, fixed in formaline and embedded in paraffin. Histological evaluation was
done in blinded fashion (ISHLT 1999/rank scale). The mean and standard error of the mean (PaO2) or the median and range (rejection
grading) are given. ANOVA followed by planned comparison for the PaO2 and Kruskal–Wallis ANOVA for rejection grading were applied,
p , 0:05 considered significant. Results: Arterial PaO2 on day 5 was very low in animals treated with subtherapeutic dosages of either
cyclosporine A (48 ^ 10 mmHg), calcitriol (51 ^ 3) or tacrolimus (86 ^ 22). Combined treatment with cyclosporine A and calcitriol
revealed a significant improvement (248 ^ 78; p , 0:05 vs. other groups), whereas the combination of tacrolimus with calcitriol did not
reveal any benefit (65 ^ 9). Rejection grading with these subtherapeutic doses did not show any significant difference between groups.
Conclusions: Our data indicate that cyclosporine A, but not tacrolimus, has a strong additive effect with calcitriol on acute rat lung allograft
rejection.
q 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Lung transplantation is an established therapeutic option
in end-stage pulmonary disease. However, either acute or
chronic rejection episodes limit the long-term survival of
lung transplant recipients. Conventional immunosuppres-
sive drugs such as cyclosporine A exert their effect at doses
close to the toxic range. In addition, the high level of
immunosuppression as compared to other solid organ
transplant recipients causes numerous side effects of the
different drugs. The addition of new immunosuppressive
substances may help to reduce the dose of the established
immunosuppressive drugs and therefore reduce toxic side
effects, e.g. nephrotoxicity of cyclosporine A.
A substantial effect of the active form of vitamin D3,
calcitriol, on acute rejection has been observed in different
models of solid organ transplantation [1–3], however,
clinical use of calcitriol in high doses is hindered by
development of hypercalcemia and hypercalcuria [4].
Therefore, this study evaluated the effect of subtherapeutic
doses of calcitriol in combination with two clinically
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established immunotherapeutic drugs on acute rejection in a
major mismatched orthotopic rat lung allotransplantation
model.
2. Methods
2.1. Experimental groups
A model of allogeneic left lung allotransplantation in rats
with one major and one minor immunological mismatch
(Donor Brown–Norway; Recipient Fischer F344; obtained
from Harlan Netherlands B.V., Ad Horst, Netherlands) was
applied. Animals received conventional food ad libitum.
No specific low calcium diet was applied. Five groups
(n ¼ 5/group) were analyzed: I. cyclosporine A, II.
cyclosporine A and ViD3, III. ViD3, IV. tacrolimus and
ViD3, V. tacrolimus. For immunosuppression, the following
subtherapeutic doses were used: ViD3 0.5 mg/kg/day i.p.,
cyclosporine A 2.5 mg/kg/day i.p., and tacrolimus
40 mg/kg/day i.m. The injections were performed until
sacrifice after 5 days starting from the day of
transplantation.
Calcitriol (Rocaltrolw) 10 ml solution, 1 mg/ml, was
provided by Roche, Basel, Switzerland. Cyclosporine A
(Sandimmunw) was provided by Novartis Pharma AG,
Basel, Switzerland and diluted in castor oil in a ratio of 1:9,
and tacrolimus (Prografw) was obtained from Fujisawa
GmbH, Munich, Germany.
All animals received humane care in compliance with the
‘Principles of Laboratory Animal Care’, formulated by the
National Society for Medical Research, and the ‘Guide for
the Care and Use of Laboratory Animals’, prepared by the
Institute of Laboratory Animal Research and published by
the National Institutes of Health (NIH Pub. No. 86-23,
revised 1985). The protocol was approved by the local
animal study committee.
2.2. Operative procedure
2.2.1. Donor
The animal is anaesthetized in a glass chamber by
inhaling 4% Halothane (SIGMA, Buchs, Switzerland).
Thiopental (Penthotalw, Abbott AG, Baar, Switzerland) at
a dosage of 50 mg/kg body weight is injected i.p. Heparine
(Liqueminw, Roche Pharma, Reinach, Switzerland) is
administered by injection into the penile vein (500 IU/kg
body weight). A tracheostomy is performed and the animal
is ventilated with a 14 GA catheter (Insytew, Becton
Dickinson, Sandy, UT, USA) with 100% oxygen, a
breathing frequency of 100/min and a tidal volume of
10 ml/kg body weight by a Harvard rodent ventilator
(Model 683, Harvard Apparatus, South Natick, MA,
USA). After cutting the inferior vena cava and left appendix
of the heart, a small silicon hose is inserted into the main
pulmonary artery (PA) via an incision in the right ventricle.
Both lungs are flushed with 20 ml of LPD solution
(Perfadexw, Medisan Pharmaceutics, Uppsala, Sweden) at
a pressure of 20 cm H20. The trachea is then tied with the
lungs in end-inspiratory position. The heart–lung block is
removed and the left lung is separated ex vivo from the heart
and right lung. Small plastic cuffs are placed around the PA
and vein [5], the vessels are everted and tied onto the cuff
and fastened with 8-0 monofilament thread (Surgiprow,
USSC, Norwalk, CT, USA). The lung is stored in LPD
solution at 10 8C until implantation.
2.2.2. Recipient
The recipient is anaesthetized by breathing 4%
Halothane in a glass chamber, intubated, and anaesthesia
is maintained with Halothane. A left thoracotomy is
performed in the fourth intercostal space. The left hilum is
dissected, and removable microvascular clips are put onto
the left PA and left pulmonary vein (PV). The left main
bronchus is ligated with 6-0 polyfilament thread (Sofsilkw,
USSC, Norwalk, CT, USA) and cut off. An incision is made
in both PV and PA. The vessels are flushed with heparinized
saline solution. The cuffs of the donor lung are inserted into
the recipient’s vessels, and 6-0 polyfilament ligatures
(Sofsilkw) are placed around the cuffs and tied. The native
PA and PV are cut off beyond the anastomosis and the
native lung is removed. A 9-0 monofilament running over-
and-over continuous suture (Monosofw, Tyco Healthcare,
Wollerau, Switzerland) is employed for bronchial anasto-
mosis. Ventilation and then retrograde followed by ante-
rograde perfusion of the graft are restored by removing the
clips from left bronchus, PV and PA, respectively. A small
chest drain is inserted to the left hemithorax, and the
thoracotomy is closed with four layers of continuous suture.
The chest drainage is removed after the animal restores
spontaneous breathing, and the animal is extubated.
2.3. Statistics
For continuous data (arterial oxygen content), all values
are given as mean ^ standard error of the mean. Rejection
grading is given as the median and range.
As PaO2 values did not fulfill homogeneity criteria of
variances, ANOVA followed by planned comparison with
contrast vector analysis was performed on log-transformed
data. The comparison of rejection grading was done by the
non-parametric Kruskal–Wallis ANOVA.
2.4. Assessment
2.4.1. Graft function
Five days after transplantation, the recipient animal is
preanaesthetized in a glass chamber inhaling 4% Halothane.
Thiopental (50 mg/kg body weight) is injected i.p. The
animal is ventilated via a tracheostomy by a Harvard
Rodent Ventilator with 100% oxygen, a breathing
frequency of 100/min and a tidal volume of 8 ml/kg.
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A thoraco-laparotomy in the anterior midline is performed.
Microvascular clips are put on the right main bronchus and
right PA in order to ventilate and perfuse only the isolated
left lung graft. Five minutes after occlusion, a steady state is
reached and 300 ml of blood is aspirated from the aortic arch
to a syringe (Radiometer Picoe 50, Copenhagen, Denmark)
for blood gas assessment (Radiometer ABL 700 Serie,
Copenhagen, Denmark). Subsequently, the inferior vena
cava and left appendix of the heart are incised and a small
silicon hose is inserted into the main PA via an incision in
the right ventricle. The lungs are then flushed with 20 ml of
0.9% saline solution under a pressure of 20 cm H2O. The
heart–lung block is explanted and tissue samples are put in
10% formaline solution (SIGMA, Buchs, Switzerland) for
histological analysis.
2.4.2. Histology
The histological assessment was done by a trained lung
pathologist in blinded fashion according to the Working
Formulation for the Classification of Pulmonary Allograft
Rejection of the International Society for Heart and Lung
Transplantation [6].
3. Results
3.1. Characterisation of experimental groups
Donor and recipient rats weighed 250 ^ 20 g, with no
statistical difference between groups. The entire transplan-
tation procedure (donor lung explantation, ex vivo prepa-
ration and implantation) took a mean of 126 ^ 10 min.
Warm ischaemic time was 21 ^ 3 min, without statistical
difference between groups. Ten recipients died due to
technical failures, and additional transplantations were
carried out to replace these animals.
3.2. Graft function
The results of blood gas analysis are summarized in
Fig. 1. Overall ANOVA revealed a statistically significant
difference between groups ðP ¼ 0:004Þ. Combined treat-
ment with cyclosporine A and calcitriol resulted in a
significant improvement of graft function 5 days post-
transplant (248 ^ 78 mmHg; p ¼ 0:0002 vs. all other
groups), as compared to single treatment with either
cyclosporine A (48 ^ 10; p ¼ 0:00003), calcitriol
(51 ^ 3; p ¼ 0:001) or tacrolimus (86 ^ 22; p ¼ 0:003).
Interestingly, the combination of subtherapeutic doses of
tacrolimus and calcitriol did not reveal any benefit (65 ^ 9;
p ¼ 0:4 vs. all other groups; p ¼ 0:4 vs. calcitriol group).
3.3. Rejection grading
The histopathological assessment (Table 1) demon-
strated no significant difference between the groups despite
significant differences in graft function (overall group
comparison for perivascular rejection p ¼ 0:76; for peri-
bronchial rejection p ¼ 0:11). In addition, group compari-
son by the Mann–Witney U test even without Bonferroni
correction for multiple testing did not reveal any significant
differences.
4. Discussion
This study demonstrated a significant improvement of
graft function, as assessed by arterial oxygen content, by a
combined treatment with subtherapeutic doses of calcitriol
and cyclosporine A 5 days after left lung allotransplantation,
whereas a combination of calcitriol with tacrolimus did not
reveal any protection against rejection. No beneficial effect
of single treatment with one of the established immuno-
suppressive agents or with calcitriol at these low doses was
observed.
The sterol hormone 1,25-dihydroxycholecalciferol (1,25-
dihydroxyvitamin D3, calcitriol), the active form of vitamin
D3, was considered to be a regulator of calcium, phosphorus
and bone metabolism only in mammals, cholecalciferol is
hydroxylated on C-25 in the liver and on C-1 in the kidneys
until the late 1970s [7]. During the past, additional effects on
the differentiation of hematopoetic cells, secretion of
prolactin and insulin and differentiation of epidermal cells
have been elucidated, and the discovery of vitamin D
receptors (VDR) in a variety of cancer cells finally led to
experimental applications in the treatment of carcinoma by
induction of p53-independent apoptosis. In the 1980s, the
immunoregulatory properties of calcitriol have been
discovered and it has been shown that calcitriol suppresses
T-helper cell mediated delayed hypersensitivity. Further
Fig. 1. Significant improvement of arterial oxygen content by combined
treatment with calcitriol and cyclosporine A.
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research in the field of autoimmune diseases was very
promising. The in vivo effectiveness of calcitriol treatment
in lupus nephritis in mice [8], Heymann’s nephritis [9],
experimental autoimmune thyroiditis and an experimental
model of arthritis [10] led to successful application in solid
organ transplantation models [2,3]. The immunosuppressive
properties of calcitriol are mediated by cells possessing the
nuclear VDR [7]. VDRs are present not only in the intestine,
bone and kidney, but also in islet cells of the pancreas, in the
parathyroid gland, hematopoetic cells, promyelocytes,
activated lymphocytes, T-cells of thymus, keratinocytes of
reproductive organs, and skin. They regulate transcription
similarly to other members of steroid–thyroid hormone
superfamily [7]. The VDR binds to the DR-3 promoter
region of target genes to stimulate or suppress transcription,
followed by translation of characteristic proteins. Calcitriol
stimulates the cell to differentiate into the final form and
then stops further proliferation (e.g. promyelocytes into
monocytes).
In the field of transplantation, the effect of calcitriol on a
subtype of antigen-presenting cells, in particular dendritic
cells (DCs), seems to be of highest importance. These DCs
undergo a process of maturation after the acquisition of
antigen, which results in the upregulation of MHC and
costimulatory ligands on the cell surface and in secretion of
immunomodulatory cytokines. In this mature state, DCs are
primed to activate T-cells in an antigen-specific fashion.
The addition of calcitriol to cell cultures of murine bone
marrow results in inhibited DC maturation as assessed in
reduction of MHC II levels and costimulatory ligands as
CD40 and B7-1 and B7-2, whereas calcitriol and also
analogs of vitamin D3 did not have any effect on bone
marrow cultures of VDR-deficient mice without attenuation
of the number of DCs [11].
In addition, calcitriol suppresses m-RNA levels of IL-2
and IFN-g, lymphokines produced by Th1 cells, and it has
been shown that serum levels of IL-2 were lower after D3
analog treatment in mice [4]. Reduced levels of IFN-g may
evoke decreased class II antigen expression on cells like
lymphocytes, monocytes, and macrophages. Other authors
suggested that calcitriol is inhibiting the production of
IL-12, which induces differentiation and activation of Th1
and NK cells by antigen presenting. In allotransplantation,
NK cells recognize the decrease of MHC antigens and
mediate target cell death by perforine, TNF-b, gramzines,
and by antibody dependent cell mediated cytotoxity. On the
other hand, IL-2 activates CD8 þ T lymphocytes, which
show cytotoxity in the context of class I MHC antigens.
Calcitriol influences not only the T-cell lymphokine
production, but also T-cell proliferation, as it arrests the
cell in the G0/G1 transition phase [12]. Calcitriol also
blocks IL-2 transcription mediated by nuclear factor of
activated T-cell (NF-AT) [13] and interacts with the T-cell
activation cascade at a level downstream calcineurin [14].
The application of a high dose treatment with calcitriol in
humans, however, is not feasible due to development of
hypercalcemia and hypercalcuria. Therefore, analogs of
vitamin D3 with a much less calcemic effect have been
developed, and applied successfully in allograft transplan-
tation models, however, even these analogs induce hyper-
calcemia during long-term treatment [4]. Therefore, this
study was conducted with calcitriol at a low subtherapeutic
dose. In addition, calcitriol is often given already to lung
transplant recipients as prophylaxis against osteoporosis
induced by cyclosporine A and corticosteroids.
Whether the effect of combined treatment with cyclo-
sporine A and calcitriol is additive or synergistic in this
model, remains speculative. The fact that cyclosporine A
also inhibits production of IL-2, but has a different
downstream pathway via association of its drug–receptor
complex with calcineurin, resulting in inhibition of T-cell
activation gene transcription, may suggest a synergistic
effect of both substances. In addition, it has been shown that
the drug LS-2616 (Linomide) can completely counteract the
immunosuppressive effect of cyclosporine A but not of an
analog of calcitriol in a model of cardiac allograft survival
[1], and in a model of phytohemagglutinin A-induced
lymphocyte proliferation. In the latter study, a clear
synergism between both substances has been demonstrated
by median effect principle analysis and confirmed in a
murine model for multiple sclerosis [15].
The combined treatment with tacrolimus and calcitriol
revealed no benefit at all. This may be due to an insufficient
dose of tracrolimus, since tacrolimus and cyclosporin A
share similar mechanism of action at the molecular level by
inhibition of the phosphorylase activity of calcineurin and
therefore, the same effect in combination with calcitriol
should be observed. On the other hand, to our knowledge,
only one study demonstrated any effect of a combined
treatment with calcitriol and tacrolimus on in vitro T-cell
proliferation and cytokine production induced by human
mixed lymphocyte reaction [16], and the dose-reducing
effect of subtherapeutic calcitriol treatment was only
fivefold in tacrolimus but 10-fold for cyclosporine A,
Table 1
Rejection grading according to the ISHLT
CyA CyA þ ViD3 ViD3 Tac þ ViD3 Tac
Vascular A3 (A3–A4) A3 (A2–A3) A3 (A3–A4) A2 (A2–A4) A3 (A2–A3)
Airway B3 (B2–B4) B3 (B2–B4) B4 (B3–B4) B3 (B2–B3) B3 (B2–B3)
No significant differences between groups were observed.
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suggesting that despite comparable mechanism of action,
these two immunosuppressants differ in their additive effect
with calcitriol.
We were surprised that despite significant improvement
in the group receiving combined subtherapeutic treatment
with cyclosporine A and calcitriol, no difference regarding
rejection grading was observed. Therefore, all slides were
re-analyzed by another expert lung pathologist (data not
shown). No differences regarding perivascular grading, and
only very minor non-significant differences regarding
peribronchial grading were observed. On the other hand, it
is known that histological signs of allograft rejection in rats
occur very early and continue more rapidly as compared to
canine, baboons and humans, with a massive influx of
leucocytes from the second day onward [17]. In another
study by our group, arterial blood gas analysis at day 3 in the
same strain combination used here reveals a preserved graft
function with a mean PaO2 of about 230 mmHg despite
significant signs of rejection [18]. We therefore speculate
that in rats, signs of rejection may occur without significant
impact of rejection on allograft function, questioning the
validity of the ISHLT scoring for rodents at least in early
and minor rejection.
In conclusion, calcitriol can be considered a new experi-
mental immunosuppressant, improving lung allograft
function in combination with cyclosporine A even at
subtherapeutic doses. Further studies are needed to confirm
these results with less hypercalcemic analogs of calcitriol
which may be feasible for long-term application in human
lung transplant recipients.
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Appendix A. Conference discussion
Dr C. Yankah (Berlin, Germany): My first question is about your
experimental design. How long was the rejection time in your control group?
Dr Stammberger: We assessed the animals 5 days after transplantation,
as it is well known in this strain combination that you’ll always see a
complete rejection of the allograft after 5 days.
Dr Yankah: Can you describe the pharmacokinetics of the cyclosporine in
the rats? Because there might be fluctuations in the blood levels of the
cyclosporine in the rats which might then also influence the degree of
Interleukin-2 production and T-lymphocyte activation, depending on the mode
of application. Did you observe such variations in the CsA levels in your series?
Dr Stammberger: We used a preparation which is also used in humans,
Sandimmune, and we applied it via intraperitoneal injection. However, we
did not take any blood samples and check for levels of cyclosporine A, so I
can’t focus on variations in the CsA levels.
Dr C. Maurus (Zurich, Switzerland): Do you have any idea about the
mechanism of the additive effect of cyclosporine and vitamin D-3?
Dr Stammberger: It is well known that both substances reduce
production of IL-2. In addition, vitamin D-3 reduces IL-12 production. It is,
however, suggested by recent publications that the main effect of vitamin
D-3 is impairment of the maturation of dendritic cells and their ability to
activate T-lymphocytes. So there are different downstream pathways
between vitamin D-3 and cyclosporine A.
Dr Maurus: Regarding the reduction of IL-12: is there an effect on
natural killer cells?
Dr Stammberger: Yes, there is also an effect on natural killer cell
activity, that’s right.
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